Market capitalization | $37.52m |
Enterprise Value | $28.77m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 84.62 |
P/S ratio (TTM) P/S ratio | 110.35 |
P/B ratio (TTM) P/B ratio | 3.36 |
Revenue growth (TTM) Revenue growth | 94.44% |
Revenue (TTM) Revenue | $340.00k |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
2 Analysts have issued a Lexaria Bioscience Corp forecast:
2 Analysts have issued a Lexaria Bioscience Corp forecast:
May '24 |
+/-
%
|
||
Revenue | 0.34 0.34 |
0%
0%
|
|
Gross Profit | 0.14 0.14 |
0%
0%
|
|
EBITDA | -6.75 -6.75 |
0%
0%
|
EBIT (Operating Income) EBIT | -6.90 -6.90 |
0%
0%
|
Net Profit | -6.89 -6.89 |
0%
0%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Lexaria Bioscience Corp. is a proprietary drug delivery technology company. Its technology DehydraTECH, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing. The company's technology can be applied to many different ingestible product formats, including foods, beverages, oral suspensions, tablets, and capsules. DehydraTECH increases bio-absorption, reduces time of onset, and masks unwanted tastes for orally administered bioactive molecules, including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. Lexaria has licensed DehydraTECH to multiple companies in the cannabis industry for use in cannabinoid beverages, edibles and oral products; and to a tobacco producer for the development of smokeless, oral-based nicotine products. The company was founded on December 9, 2004 and is headquartered in Kelowna, Canada.
Head office | United States |
CEO | Richard Christopher |
Employees | 5 |
Founded | 2004 |
Website | www.lexariabioscience.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.